Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

201. Low protein diets for non-diabetic adults with chronic kidney disease. (Full text)

Low protein diets for non-diabetic adults with chronic kidney disease. Chronic kidney disease (CKD) is defined as reduced function of the kidneys present for 3 months or longer with adverse implications for health and survival. For several decades low protein diets have been proposed for participants with CKD with the aim of slowing the progression to end-stage kidney disease (ESKD) and delaying the onset of renal replacement therapy. However the relative benefits and harms of dietary protein (...) relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We included randomised controlled trials (RCTs) or quasi RCTs in which adults with non-diabetic chronic kidney disease (stages 3 to 5) not on dialysis were randomised to receive a very low protein intake (0.3 to 0.4 g/kg/d) compared with a low protein intake (0.5 to 0.6 g/kg/d

2018 Cochrane PubMed abstract

202. Association between MPO-463G > A polymorphism and chronic kidney disease: a meta-analysis (Full text)

Association between MPO-463G > A polymorphism and chronic kidney disease: a meta-analysis Previous studies have shown that MPO -463G > A (rs2333227) might be associated with chronic kidney disease (CKD) susceptibility, but sample sizes of those studies are relatively small. Hence, we decided to perform a meta-analysis to evaluate the association. Methods/main results: Two investigators search databases systematically and independently. Odds ratios and 95% confidence intervals were used

2018 Renal failure PubMed abstract

203. Treatment of Hypertension in Association With Nondiabetic Chronic Kidney Disease

combinations. 4. In most cases, combination therapy with other antihypertensive agents might be needed to reach target BP levels (Grade D). This recommendation is based on expert consensus. 5. The combination of an ACE inhibitor and ARB is not recommended for patients with nonproteinuric chronic kidney disease (Grade B). Dual renin-angiotensin system (RAS) inhibition has been shown to reduce significantly proteinuria , a surrogate endpoint for cardiovascular disease, and renal impairment in patients (...) to develop future recommendations for these patient populations. References Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood- pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877-84. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease study. Ann Intern

2018 Hypertension Canada

204. Do thiazides work in patients with chronic kidney disease?

Do thiazides work in patients with chronic kidney disease? Do Thiazides Work in Patients With Chronic Kidney Disease? – Clinical Correlations Search Do Thiazides Work in Patients With Chronic Kidney Disease? October 4, 2018 4 min read By Hannah Friedman Peer Reviewed It is a commonly seen scenario on the wards: a patient with a past medical history of heart failure and stage 4 chronic kidney disease presents with progressive shortness of breath and worsening lower extremity edema. The patient (...) (Stage 4-5). However, recent literature . [1] Recent reports estimate that 13.1% of the US population has chronic kidney disease (CKD), with 8% having at least stage 3 CKD. [2] These patients have a , [3] and this risk worsens as the disease progresses. Thiazides and thiazide-like diuretics act on the distal convoluted tubule of the nephron, specifically on the . [4] This mechanism makes thiazides useful not just as antihypertensives, but also as diuretics in volume-overloaded patients. Thiazides

2018 Clinical Correlations

205. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial (Full text)

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac biomarkers in people with moderate to severe chronic kidney disease are unknown.The UK HARP-III trial (United Kingdom Heart and Renal Protection-III), a randomized double-blind trial, included 414 (...) (36.7% versus 28.0%; rate ratio, 1.35; 95% CI, 0.96-1.90), and potassium ≥5.5 mmol/L (32% versus 24%, P=0.10) was not significantly different between randomized groups.Over 12 months, sacubitril/valsartan has similar effects on kidney function and albuminuria to irbesartan, but it has the additional effect of lowering blood pressure and cardiac biomarkers in people with chronic kidney disease.URL: http://www.isrctn.com . Unique identifier: ISRCTN11958993.

2018 EvidenceUpdates PubMed abstract

206. Treating endothelial dysfunction with vitamin D in chronic kidney disease: a meta-analysis. (Full text)

Treating endothelial dysfunction with vitamin D in chronic kidney disease: a meta-analysis. Vitamin D deficiency is common in patients with chronic kidney disease (CKD), and is associated with endothelial dysfunction and cardiovascular disease. We performed a meta-analysis to assess the effect of vitamin D treatment on flow mediated vasodilation (FMD) in CKD patients.PubMed/Medline, Web of Science, Embase and Cochrane trials and reviews were searched systematically for randomized controlled (...) of vitamin D on vascular disease in CKD. Limitations of this meta-analysis are the small number of studies performed, and the short duration of intervention.

2018 BMC Nephrology PubMed abstract

207. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. (Full text)

Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Diabetes is the commonest cause of chronic kidney disease (CKD). Both conditions commonly co-exist. Glucometabolic changes and concurrent dialysis in diabetes and CKD make glucose-lowering challenging, increasing the risk of hypoglycaemia. Glucose-lowering agents have been mainly studied in people with near-normal kidney function. It is important to characterise existing knowledge of glucose (...) = 28%) and albuminuria (MD -8.14 mg/mmol creatinine, -14.51 to -1.77; I2 = 11%; low certainty evidence). SGLT2 inhibitors may have little or no effect on the risk of cardiovascular death, hypoglycaemia, acute kidney injury (AKI), and urinary tract infection (low certainty evidence). It is uncertain whether SGLT2 inhibitors have any effect on death, end-stage kidney disease (ESKD), hypovolaemia, fractures, diabetic ketoacidosis, or discontinuation due to adverse effects (very low certainty evidence

2018 Cochrane PubMed abstract

208. Association between fibre intake and indoxyl sulphate/P-cresyl sulphate in patients with chronic kidney disease: Meta-analysis and systematic review of experimental studies. (Abstract)

Association between fibre intake and indoxyl sulphate/P-cresyl sulphate in patients with chronic kidney disease: Meta-analysis and systematic review of experimental studies. Indoxyl sulphate (IS) and p-cresyl sulphate (PCS), which are difficult to excrete adequately out of the body, are closely related to the progression of chronic kidney disease (CKD) and various deuteropathy. Better than peritoneal dialysis (PD) and haemodialysis (HD), dietary fibre has been considered to reduce IS and PCS

2018 Clinical nutrition (Edinburgh, Scotland)

209. Chronic kidney disease

retinopathy diabetes mellitus hypertension age >50 years childhood kidney disease smoking obesity black or Hispanic ethnicity family history of chronic kidney disease autoimmune disorders male sex long-term use of NSAIDs Diagnostic investigations serum creatinine urinalysis urine microalbumin renal ultrasound estimation of GFR renal biopsy plain abdominal radiograph abdominal CT abdominal MRI Treatment algorithm ACUTE Contributors Authors Assistant Professor of Medicine University of Arkansas for Medical (...) is determined only by laboratory studies. Glycaemic control for diabetic nephropathy and optimisation of blood pressure are key in slowing the progression of disease. Increased risk for cardiovascular disease. Definition Chronic kidney disease (CKD), also known as chronic renal failure, is defined by either a pathological abnormality of the kidney, such as haematuria and/or proteinuria, or a reduction in the glomerular filtration rate to <60 mL/minute/1.73 m² for ≥3 months' duration. Kidney Disease

2018 BMJ Best Practice

210. The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease (Full text)

The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease The purpose of this study was to analyze the effects of hypoxia-inducible factor (HIF) stabilizers on anemia in non-dialysis-dependent (NDD) and dialysis-dependent (DD) chronic kidney disease (CKD) patients.Published studies were extracted from PubMed, China Biological Medicine Database (CBM), Wanfang database, and Cochrane Library on March 10, 2018, and relevant studies were

2018 Drug design, development and therapy PubMed abstract

211. Work of being an adult patient with chronic kidney disease: a systematic review of qualitative studies. (Full text)

Work of being an adult patient with chronic kidney disease: a systematic review of qualitative studies. Chronic kidney disease (CKD) requires patients and caregivers to invest in self-care and self-management of their disease. We aimed to describe the work for adult patients that follows from these investments and develop an understanding of burden of treatment (BoT).Systematic review of qualitative primary studies that builds on EXPERTS1 Protocol, PROSPERO registration number: CRD42014014547 (...) to and from haemodialysis centre, with variable availability and cost, was a common problem, aggravated for patients in non-urban areas, or with young children, and low resources. Additional work for those uninsured or underinsured included fund-raising. Transplanted patients needed to manage finances and responsibilities in an uncertain context. Information on the disease, treatment options and immunosuppressants side effects was a widespread problem.Being a person with end-stage kidney disease always

2018 BMJ open PubMed abstract

212. Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial (Full text)

Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial The optimal revascularization strategy for patients with left main coronary artery disease (LMCAD) and chronic kidney disease (CKD) remains unclear.This study investigated the comparative effectiveness of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery in patients with LMCAD and low or intermediate anatomical complexity according to baseline renal (...) function from the multicenter randomized EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial.CKD was defined as an estimated glomerular filtration rate <60 ml/min/1.73 m2 using the CKD Epidemiology Collaboration equation. Acute renal failure (ARF) was defined as a serum creatinine increase ≥5.0 mg/dl from baseline or a new requirement for dialysis. The primary composite endpoint was the composite of death, myocardial infarction (MI

2018 EvidenceUpdates PubMed abstract

213. Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625–637 (Full text)

Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625–637 [This corrects the article DOI: 10.1016/j.ekir.2018.01.002.].

2018 Kidney international reports PubMed abstract

214. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). (Full text)

Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Phosphate binders are used to reduce positive phosphate balance and to lower serum phosphate levels for people with chronic kidney disease (CKD) with the aim to prevent progression of chronic kidney disease-mineral and bone disorder (CKD-MBD). This is an update of a review first published in 2011.The aim of this review was to assess the benefits and harms of phosphate binders for people (...) with CKD with particular reference to relevant biochemical end-points, musculoskeletal and cardiovascular morbidity, hospitalisation, and death.We searched the Cochrane Kidney and Transplant Register of Studies up to 12 July 2018 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal

2018 Cochrane PubMed abstract

215. Correlation between Soluble α-Klotho and Renal Function in Patients with Chronic Kidney Disease: A Review and Meta-Analysis (Full text)

Correlation between Soluble α-Klotho and Renal Function in Patients with Chronic Kidney Disease: A Review and Meta-Analysis Over decades, numerous inconsistent studies are reported on the relationship between soluble α-Klotho and renal function in patients with chronic kidney disease (CKD). This study aims to perform a meta-analysis to figure out the correlations between soluble α-Klotho and renal function in patients with CKD.We searched medical and scientific literature databases, PubMed (...) and EMBASE (from the inception to October 2017), for publications that reported studies on associations between soluble α-Klotho and renal function in patients with CKD. Only publications in English were extracted. Summary correlation coefficient (r) values were extracted from each study, and 95% confidence intervals (CIs) were calculated. Publication bias was tested, and sensitivity and subgroup analyses were performed to investigate potential heterogeneity.Of 611 studies, 9 publications with 1457

2018 BioMed research international PubMed abstract

216. Chronic kidney disease

disease —mineral and bone disorder (CKD-MBD). Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease –mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7 2017 10. Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary (...) on management of older patients with chronic kidney disease stage 3b or higher (eGFR chronic kidney disease stage 3b or higher (eGFR 2016 3. Chronic kidney disease - not diabetic Chronic kidney disease - not diabetic - NICE CKS Clinical Knowledge Summaries Share Chronic kidney disease - not diabetic - Summary Chronic kidney disease (CKD) is an abnormality of kidney function or structure that is present for more than 3 months, with implications for health. Complications of CKD include worsening renal disease

2018 Trip Latest and Greatest

217. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study (Full text)

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with type 2 diabetes (T2D) and moderate renal impairment (estimated glomerular filtration rate [eGFR], 45-59 mL/min/1.73 m2 ; chronic kidney disease [CKD] stage 3A

2018 EvidenceUpdates PubMed abstract

218. Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development (Full text)

Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development Chronic kidney disease of unknown aetiology (CKDu) refers to the epidemic level of incidence of CKD in several low- and middle-income countries, usually near the equator, for which the aetiology has not been identified. CKDu represents a form of CKD hotspot, defined as a country, region, community or ethnicity with a higher than average incidence of CKD. In terms (...) of the number of persons affected, the so-called hypertensive nephropathy of African Americans probably represents the largest CKD hotspot, which is largely driven by variants of the APOL1 gene, questioning the very existence of hypertensive nephropathy and illustrating how kidney disease driven by genetic predisposition may underlie some forms of hypertension. For CKDu, hard physical work leading to dehydration (the first global warming-related disease?) and local toxins are leading aetiological candidates

2018 Clinical kidney journal PubMed abstract

219. Probiotics, prebiotics and synbiotics for chronic kidney disease: protocol for a systematic review and meta-analysis. (Full text)

Probiotics, prebiotics and synbiotics for chronic kidney disease: protocol for a systematic review and meta-analysis. There is a growing interest in probiotic, prebiotic and synbiotic supplements for patients with chronic kidney disease (CKD). However, a systematic review and evaluation is lacking. The purpose of the present study is to assess the efficacy and safety of probiotics, prebiotics and synbiotics for non-dialysis or non-renal transplant patients with CKD.An extensive literature (...) outcome measures are uraemic toxins. Secondary outcomes include kidney function, adverse cardiovascular events, all-cause mortality, cause-specific death, progression to end-stage kidney disease, quality of life, gastrointestinal function and adverse events. Data will be synthesised using appropriate statistical methods. The quality of evidence for each outcome will be assessed using the Grading of Recommendations Assessment, Development and Evaluation approach.No ethical approval is required

2018 BMJ open PubMed abstract

220. Chronic Kidney Disease, Queensland (CKD.QLD) Registry: Management of CKD With Telenephrology (Full text)

Chronic Kidney Disease, Queensland (CKD.QLD) Registry: Management of CKD With Telenephrology Enabled by the Chronic Kidney Disease, Queensland (CKD.QLD) Registry, we aim to outline the structure, implementation, and outcomes of telenephrology clinics for the management of patients with chronic kidney disease (CKD) in rural, regional, and remote areas of the Darling Downs region in Queensland, Australia.This is an observational registry-based study involving adult patients with CKD, attending

2018 Kidney international reports PubMed abstract